These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 10860888)
1. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity. Brand D; Lemiale F; Thibault G; Verrier B; Lebigot S; Roingeard P; Buzelay L; Brunet S; Barin F Virology; 2000 Jun; 271(2):350-62. PubMed ID: 10860888 [TBL] [Abstract][Full Text] [Related]
2. The transmembrane protein of HIV-1 primary isolates modulates cell surface expression of their envelope glycoproteins. Lebigot S; Roingeard P; Thibault G; Lemiale F; Verrier B; Barin F; Brand D Virology; 2001 Nov; 290(1):136-42. PubMed ID: 11882998 [TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model. Notka F; Stahl-Hennig C; Dittmer U; Wolf H; Wagner R Biol Chem; 1999 Mar; 380(3):341-52. PubMed ID: 10223337 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: a comparative study using multivalent vaccine approaches. Lemiale F; Brand D; Lebigot S; Verrier B; Buzelay L; Brunet S; Barin F J Acquir Immune Defic Syndr; 2001 Apr; 26(5):413-22. PubMed ID: 11391160 [TBL] [Abstract][Full Text] [Related]
5. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Pancera M; Wyatt R Virology; 2005 Feb; 332(1):145-56. PubMed ID: 15661147 [TBL] [Abstract][Full Text] [Related]
6. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. Binley JM; Sanders RW; Clas B; Schuelke N; Master A; Guo Y; Kajumo F; Anselma DJ; Maddon PJ; Olson WC; Moore JP J Virol; 2000 Jan; 74(2):627-43. PubMed ID: 10623724 [TBL] [Abstract][Full Text] [Related]
7. Chimeric synthetic peptide as antigen for immunodiagnosis of HIV-1 infection. Hernández M; Pozo L; Gómez I; Melchor A Biochem Biophys Res Commun; 2000 May; 272(1):259-62. PubMed ID: 10872836 [TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus type 1 subtype E envelope recombinant peptides containing naturally immunogenic epitopes. Chang SY; Vithayasai V; Vithayasai P; Essex M; Lee TH J Infect Dis; 2000 Aug; 182(2):442-50. PubMed ID: 10915074 [TBL] [Abstract][Full Text] [Related]
9. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state. Sadler K; Zhang Y; Xu J; Yu Q; Tam JP Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371 [TBL] [Abstract][Full Text] [Related]
10. Expression and detection of macrophage-tropic HIV-1 gp120 in the brain using conformation-dependent antibodies. Altmeyer R; Mordelet E; Girard M; Vidal C Virology; 1999 Jul; 259(2):314-23. PubMed ID: 10388656 [TBL] [Abstract][Full Text] [Related]
11. Resistance to viral infection by intraepithelial lymphocytes in HIV-1 P18-I10-specific T-cell receptor transgenic mice. Kuribayashi H; Wakabayashi A; Shimizu M; Kaneko H; Norose Y; Nakagawa Y; Wang J; Kumagai Y; Margulies DH; Takahashi H Biochem Biophys Res Commun; 2004 Apr; 316(2):356-63. PubMed ID: 15020225 [TBL] [Abstract][Full Text] [Related]
12. Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Jeffs SA; Goriup S; Kebble B; Crane D; Bolgiano B; Sattentau Q; Jones S; Holmes H Vaccine; 2004 Feb; 22(8):1032-46. PubMed ID: 15161081 [TBL] [Abstract][Full Text] [Related]
13. [HIV-1 env glycoprotein gp120 and gp160 expressed in vaccinia virus system and their antigenicity analysis]. Chen Y; Garcia R; Baralle FE Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Apr; 19(2):120-6. PubMed ID: 10453506 [TBL] [Abstract][Full Text] [Related]
14. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein. Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170 [TBL] [Abstract][Full Text] [Related]
15. Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. Liu F; Mboudjeka I; Shen S; Chou TH; Wang S; Ross TM; Lu S Vaccine; 2004 Apr; 22(13-14):1764-72. PubMed ID: 15068860 [TBL] [Abstract][Full Text] [Related]
16. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. Gao F; Weaver EA; Lu Z; Li Y; Liao HX; Ma B; Alam SM; Scearce RM; Sutherland LL; Yu JS; Decker JM; Shaw GM; Montefiori DC; Korber BT; Hahn BH; Haynes BF J Virol; 2005 Jan; 79(2):1154-63. PubMed ID: 15613343 [TBL] [Abstract][Full Text] [Related]
17. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex. Welman M; Lemay G; Cohen EA Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629 [TBL] [Abstract][Full Text] [Related]
18. Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease. Song B; Cayabyab M; Phan N; Wang L; Axthelm MK; Letvin NL; Sodroski JG Virology; 2004 Apr; 322(1):168-81. PubMed ID: 15063126 [TBL] [Abstract][Full Text] [Related]
19. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. Berkower I; Raymond M; Muller J; Spadaccini A; Aberdeen A Virology; 2004 Mar; 321(1):75-86. PubMed ID: 15033567 [TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. Brand D; Lemiale F; Turbica I; Buzelay L; Brunet S; Barin F AIDS Res Hum Retroviruses; 1998 Oct; 14(15):1369-77. PubMed ID: 9788678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]